Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Enterprise Therapeutics

Enterprise Therapeutics
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$40.8M LATEST DEAL AMOUNT
7 INVESTORS
Description

Developer of novel therapies for the treatment of respiratory diseases. The company's drugs and novel therapies targets the underlying mechanisms of mucus congestion, which reduces the frequency of lung infections, enabling patients to begin a more successful treatment and improve their quality of life.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Sussex Innovation Centre
  • University of Sussex, Science Park Square, Falmer
  • Brighton BN1 9SB
  • England, United Kingdom

+44 01273 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Enterprise Therapeutics’s full profile, request a free trial.

Enterprise Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 12-Apr-2018 $40.8M 000.00 Completed Generating Revenue/Not Profitable
3. Grant 05-Apr-2017 000.00 Completed Generating Revenue/Not Profitable
2. Early Stage VC 10-Nov-2016 $5.43M $11.6M 000.00 Completed Generating Revenue/Not Profitable
1. Early Stage VC (Series A) 20-May-2015 $6.15M $6.15M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Enterprise Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Enterprise Therapeutics Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evox Therapeutics Venture Capital-Backed Oxford, United Kingdom 0 000.00 0000000000 000.00
000000000 Formerly VC-backed Southampton, United Kingdom 0 000.00 000000000 000.00
0000000 (000000000 Venture Capital-Backed Cambridge, MA 00 0000 00000000000 0000
000000 000000 Corporation London, United Kingdom 00 000.00 000000000 000.00
00000000 000000000 Corporation Warrington, PA 00 00000 000000&0
To view this company’s complete list of competitors, request access »

Enterprise Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Forbion Venture Capital Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Versant Venture Management Venture Capital Minority 000 0000 000000 0
Cystic Fibrosis Trust Other 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Enterprise Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
John Ford Ph.D Chief Executive Officer & Board Member
Phil Boyd Ph.D Chief Financial Officer
Martin Gosling Ph.D Chief Scientific Officer & Board Member
Henry Danahay Ph.D Head, Biology

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Enterprise Therapeutics Board Members (10)

Name Representing Role Since Contact
Info
Alexander Mayweg Ph.D Versant Venture Management Board Member 000 0000
Bobby Soni Ph.D Touchstone Innovations Board Member 000 0000
David Morris MD Novartis Venture Fund Board Member 000 0000
Geert-Jan Mulder MD Forbion Board Member 000 0000
John Ford Ph.D Enterprise Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »